

Pharyngitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

https://marketpublishers.com/r/P0CB5D39F905EN.html

Date: May 2024

Pages: 131

Price: US\$ 6,499.00 (Single User License)

ID: P0CB5D39F905EN

Abstracts

The 7 major pharyngitis markets reached a value of US\$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 2.3 Billion by 2034, exhibiting a growth rate (CAGR) of 3.29% during 2024-2034.

The pharyngitis market has been comprehensively analyzed in IMARC's new report titled "Pharyngitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pharyngitis refers to a medical condition that causes inflammation or infection of the pharynx, which is the part of the throat located behind the nasal cavity and mouth. The most common symptom of the ailment is a sore throat that may be accompanied by pain or discomfort while swallowing. Numerous other indications of this disease include redness and swelling of the throat, inflammation of the tonsils, swollen lymph nodes in the neck, hoarseness or a scratchy voice, coughing, runny nose, sneezing, body aches, headaches, fever, etc. The diagnosis of pharyngitis usually involves a physical examination, evaluation of symptoms, and sometimes a throat swab to determine the presence of bacteria or viruses. Additionally, several blood tests may be performed to assess the general health of the patient and check for indications of the infection. These investigations can measure various parameters, such as white blood cell count and C-reactive protein (CRP) levels. A healthcare provider may further conduct polymerase chain reaction (PCR) testing to detect the genetic material of the pathogen causing the condition.

The increasing cases of viral and bacterial infections, which invade the healthy cells in the lining of the throat and tonsils, leading to inflammation and irritation, are primarily driving the pharyngitis market. In addition to this, the rising prevalence of exposure to dry air, smoking, pollution, etc., or numerous other environmental irritants, like allergens



and strong fumes, that can directly damage the pharyngeal tissues, is also creating a positive outlook for the market. Moreover, the widespread adoption of effective medications, such as non-steroidal anti-inflammatory drugs (NSAIDs), antivirals, antibiotics, etc., to treat the ailment or manage the disease symptoms is further bolstering the market growth. Apart from this, the inflating application of throat lozenges or sprays, which contain numbing agents like benzocaine and menthol to relieve discomfort and pain by soothing the irritated tissues, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of photobiomodulation therapy, since it uses light-emitting diodes or low-level lasers to stimulate cellular function in patients and promote healing, is expected to drive the pharyngitis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the pharyngitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for pharyngitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the pharyngitis market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023 Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain



Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario Historical, current, and future performance of the pharyngitis market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the pharyngitis market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current pharyngitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report: Market Insights

How has the pharyngitis market performed so far and how will it perform in the coming years?



What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the pharyngitis market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the pharyngitis market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of pharyngitis across the seven major markets?

What is the number of prevalent cases (2018-2034) of pharyngitis by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of pharyngitis by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with pharyngitis across the seven major markets?

What is the size of the pharyngitis patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of pharyngitis? What will be the growth rate of patients across the seven major markets?

Pharyngitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance? What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for pharyngitis drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the pharyngitis market?

What are the key regulatory events related to the pharyngitis market?

What is the structure of clinical trial landscape by status related to the pharyngitis



market?

What is the structure of clinical trial landscape by phase related to the pharyngitis market?

What is the structure of clinical trial landscape by route of administration related to the pharyngitis market?



Contents

?1 Preface

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 PHARYNGITIS - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 PHARYNGITIS - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 PHARYNGITIS - EPIDEMIOLOGY AND PATIENT POPULATION

7.1 Epidemiology - Key Insights



- 7.2 Epidemiology Scenario Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (2018-2034)
 - 7.2.4 Epidemiology by Gender (2018-2034)
 - 7.2.5 Diagnosed Cases (2018-2034)
 - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (2018-2034)
 - 7.3.4 Epidemiology by Gender (2018-2034)
 - 7.3.5 Diagnosed Cases (2018-2034)
 - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (2018-2034)
 - 7.4.4 Epidemiology by Gender (2018-2034)
 - 7.4.5 Diagnosed Cases (2018-2034)
 - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (2018-2034)
 - 7.5.4 Epidemiology by Gender (2018-2034)
 - 7.5.5 Diagnosed Cases (2018-2034)
 - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (2018-2034)
 - 7.6.4 Epidemiology by Gender (2018-2034)
 - 7.6.5 Diagnosed Cases (2018-2034)
 - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)
 - 7.7.3 Epidemiology by Age (2018-2034)



- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (2018-2034)
 - 7.8.4 Epidemiology by Gender (2018-2034)
 - 7.8.5 Diagnosed Cases (2018-2034)
 - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (2018-2034)
 - 7.9.4 Epidemiology by Gender (2018-2034)
 - 7.9.5 Diagnosed Cases (2018-2034)
 - 7.9.6 Patient Pool/Treated Cases (2018-2034)

8 PHARYNGITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 PHARYNGITIS - UNMET NEEDS

10 PHARYNGITIS - KEY ENDPOINTS OF TREATMENT

11 PHARYNGITIS - MARKETED PRODUCTS

- 11.1 List of Pharyngitis Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Moxatag (Amoxicillin extended-release) MiddleBrook
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report



12 PHARYNGITIS - PIPELINE DRUGS

- 12.1 List of Pharyngitis Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 Drug Name Company Name
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13. PHARYNGITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. PHARYNGITIS - CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 PHARYNGITIS - MARKET SCENARIO

- 15.1 Market Scenario Key Insights
- 15.2 Market Scenario Top 7 Markets
- 15.2.1 Pharyngitis Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
- 15.2.2 Pharyngitis Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario United States
 - 15.3.1 Pharyngitis Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Pharyngitis Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)



- 15.3.3 Pharyngitis Access and Reimbursement Overview
- 15.4 Market Scenario Germany
 - 15.4.1 Pharyngitis Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Pharyngitis Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Pharyngitis Access and Reimbursement Overview
- 15.5 Market Scenario France
 - 15.5.1 Pharyngitis Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Pharyngitis Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
- 15.5.3 Pharyngitis Access and Reimbursement Overview
- 15.6 Market Scenario United Kingdom
 - 15.6.1 Pharyngitis Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Pharyngitis Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Pharyngitis Access and Reimbursement Overview
- 15.7 Market Scenario Italy
 - 15.7.1 Pharyngitis Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Pharyngitis Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Pharyngitis Access and Reimbursement Overview
- 15.8 Market Scenario Spain
 - 15.8.1 Pharyngitis Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Pharyngitis Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)



- 15.8.2.2 Market Forecast by Therapies (2024-2034)
- 15.8.3 Pharyngitis Access and Reimbursement Overview
- 15.9 Market Scenario Japan
 - 15.9.1 Pharyngitis Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Pharyngitis Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Pharyngitis Access and Reimbursement Overview

16 PHARYNGITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 PHARYNGITIS MARKET - SWOT ANALYSIS

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

18 PHARYNGITIS MARKET - STRATEGIC RECOMMENDATIONS

19 APPENDIX



I would like to order

Product name: Pharyngitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and

Forecast 2024-2034

Product link: https://marketpublishers.com/r/P0CB5D39F905EN.html

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/P0CB5D39F905EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

